Back To: Home : Featured Technology : Functional Genomic Screening

CLICK HERE FOR WHAT'S NEW IN:
 

Celera enters oncology research deal with Merck
11-14-2007
SHARING OPTIONS:

ROCKVILLE, Md.—Celera, an Applera Corp. business, entered into a research collaboration with Merck & Co. in mid-September to develop biomarker and pharmacogenomic tests for cancer patients. Under the terms of the agreement, Celera will evaluate the use of certain gene expression profiles identified by Merck with the goal of developing diagnostic predictors for use in Merck's clinical trials, and to potentially form the basis for commercial companion diagnostic tests for oncology therapies. Celera will receive an undisclosed payment for this collaboration, which is expected to be completed by the end of Celera's fiscal year 2008. Celera would be eligible for an additional payment should Merck decide to transfer a Celera-validated gene expression assay to a clinical reference laboratory upon completion.  

Back


PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.